Literature DB >> 17693189

Aberrant EVI1 expression in acute myeloid leukemias associated with the t(3;8)(q26;q24).

Patrick A Lennon1, Lynne V Abruzzo, L Jeffrey Medeiros, Candy Cromwell, Xiang Zhang, Cameron C Yin, Steven M Kornblau, Marina Konopieva, Pei Lin.   

Abstract

EVI is a proto-oncogene that is activated in acute myeloid leukemia with chromosomal rearrangements that map to chromosome 3q26. We previously reported the clinicopathologic features of five cases of acute myeloid leukemia carrying t(3;8)(q26;q24). Using fluorescence in situ hybridization analysis, we demonstrate in the current study that the breakpoint on chromosome 3 is at EVI1/MDS1, and the breakpoint on chromosome 8 is just distal to the PVT1 oncogene homolog, a C-MYC activator in mice. The breakpoint on chromosome 8 was detected between the components of the LSI MYC dual-color break-apart rearrangement probe. Reverse-transcriptase polymerase chain reaction assay showed expression of EVI1 in all four cases analyzed, and DNA sequence analysis confirmed the findings. Reverse transcriptase polymerase chain reaction assay also demonstrated the expression of PVT1 and C-MYC in all four cases assessed. Western blot analysis detected EVI1 in one case analyzed. We conclude that the t(3;8)(q26;q24) results in deregulated EVI1 expression, similar to other balanced or unbalanced chromosomal translocations involving chromosome 3q26.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17693189     DOI: 10.1016/j.cancergencyto.2007.05.007

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  6 in total

Review 1.  Long non-coding RNAs and MYC association in hematological malignancies.

Authors:  Leonidas Benetatos; Agapi Benetatou; Georgios Vartholomatos
Journal:  Ann Hematol       Date:  2020-07-04       Impact factor: 3.673

Review 2.  Recent advances in the diagnosis and classification of myeloid neoplasms--comments on the 2008 WHO classification.

Authors:  C C Yin; L J Medeiros; C E Bueso-Ramos
Journal:  Int J Lab Hematol       Date:  2010-07-07       Impact factor: 2.877

Review 3.  Significance of oncogenes and tumor suppressor genes in AML prognosis.

Authors:  Maria Kavianpour; Ahmad Ahmadzadeh; Saeid Shahrabi; Najmaldin Saki
Journal:  Tumour Biol       Date:  2016-05-14

4.  Genetic variants associated with increased risk of malignant pleural mesothelioma: a genome-wide association study.

Authors:  Giuseppe Matullo; Simonetta Guarrera; Marta Betti; Giovanni Fiorito; Daniela Ferrante; Floriana Voglino; Gemma Cadby; Cornelia Di Gaetano; Fabio Rosa; Alessia Russo; Ari Hirvonen; Elisabetta Casalone; Sara Tunesi; Marina Padoan; Mara Giordano; Anna Aspesi; Caterina Casadio; Francesco Ardissone; Enrico Ruffini; Pier Giacomo Betta; Roberta Libener; Roberto Guaschino; Ezio Piccolini; Monica Neri; Arthur W B Musk; Nicholas H de Klerk; Jennie Hui; John Beilby; Alan L James; Jenette Creaney; Bruce W Robinson; Sutapa Mukherjee; Lyle J Palmer; Dario Mirabelli; Donatella Ugolini; Stefano Bonassi; Corrado Magnani; Irma Dianzani
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

5.  Gene Expression Differences between Enriched Normal and Chronic Myelogenous Leukemia Quiescent Stem/Progenitor Cells and Correlations with Biological Abnormalities.

Authors:  M Affer; S Dao; C Liu; A B Olshen; Q Mo; A Viale; C L Lambek; T G Marr; B D Clarkson
Journal:  J Oncol       Date:  2011-02-23       Impact factor: 4.375

6.  A patient with glycogen storage disease type Ib presenting with acute myeloid leukemia (AML) bearing monosomy 7 and translocation t(3;8)(q26;q24) after 14 years of treatment with granulocyte colony-stimulating factor (G-CSF): a case report.

Authors:  Thomas Schroeder; Barbara Hildebrandt; Ertan Mayatepek; Ulrich Germing; Rainer Haas
Journal:  J Med Case Rep       Date:  2008-09-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.